<span item_type="fundamental" item_id="99ea1574516d2a31f8c6af02ba594b51" counter_id="ST/US/ACUT" env="prod"></span><span item_type="announcement" item_id="518279294531210753" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.03.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -440.41 K.</p><p></p><h3>Financial Operations Overview</h3><h4>Net Loss</h4><p>AccuStem Sciences, Inc. reported a net loss of $440,408 for the three months ended March 31, 2025, compared to a net loss of $526,602 for the same period in 2024, representing a decrease of 16%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></p><h4>Operating Expenses</h4><ul><li>Research and development expenses increased to $28,346 in Q1 2025 from $23,197 in Q1 2024, primarily due to a decrease in patent-related expenses and laboratory work and consulting.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></li><li>General and administrative expenses decreased to $412,062 in Q1 2025 from $503,405 in Q1 2024, primarily due to a reduction in payroll-related costs as a result of a decrease in headcount.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities was - $290,182 for the three months ended March 31, 2025, compared to - $237,351 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></li><li>Net cash provided by financing activities was $321,517 in Q1 2025, compared to $225,243 in Q1 2024, primarily due to cash advances from a related party offset by payments on a note payable.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><p>AccuStem plans to launch its lead product candidate, the microRNA Signature Classifier (MSC) test, for clinical use in early 2026, focusing on the commercialization of its proprietary genomic test, StemPrintER, for patients with early-stage breast cancer.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></p><h4>Non-Core Business</h4><p>The company plans to offer additional “commodity” testing (e.g., next-generation sequencing) to create significant value for customers while leveraging existing laboratory equipment and processes for economy of scale and providing additional revenue opportunities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></p><h4>Funding Requirements</h4><p>AccuStem expects expenses to increase and operating losses to be generated, with an accumulated deficit of $8,467,455 as of March 31, 2025. The company anticipates needing additional funds to support product development and clinical operations, as well as commercialization efforts.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1850767/000164117225011721/form10-q.htm"></span></p>

AccuStem Sciences, Inc. | 10-Q: FY2025 Q1 EPS: USD -0.03